Complement C2 receptor inhibitor trispanning confers an increased ability to resist complement-mediated lysis in Trypanosoma cruzi

Journal of Infectious Diseases

Volumn 198, Issue 9, 2008, Pages 1276-1283

  Cestari, Igor Dos S ^a   Evans Osses, Ingrid ^a   Freitas, Juliana C ^a   Inal, Jameel M ^b,c   Ramirez, Marcel I ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C2; LECTIN; PROTEIN CRIT; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EPIMASTIGOTE; GENE OVEREXPRESSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

AMINO ACID SEQUENCE; ANIMALS; CLONING, MOLECULAR; COMPLEMENT SYSTEM PROTEINS; GENE EXPRESSION REGULATION; MOLECULAR BIOLOGY; MOLECULAR SEQUENCE DATA; ORGANISMS, GENETICALLY MODIFIED; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE; TRYPANOSOMA CRUZI;

EID: 54249162286     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592167     Document Type: Article

References (34)

1. Teixeira A R, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA. Chagas disease. Postgrad Med J 2006; 82:788-98.
2. Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypaosomiasis). Ann Trop Med Parasitol 2006; 100:663-77.
3. Dutra WO, Rocha MOC, Teixeira MM. The clinical immunology of human Chagas disease. Trends Parasitol 2005; 21:581-7.
4. Almeida IC, Ferguson MA, Schenkman S, Travassos LR. Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl- phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem J 1994; 304:793-802.
5. Ambrosio AR, Messias-Reason LJT. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation: an antibody-independent defence mechanism. Parasite Immunol 2005; 27:333-40.
6. Zulantay I, Venegas J, Apt W, Solari A. Lytic antibodies in Trypanosoma cruzi-infected persons with low parasitemia. Am J Trop Med Hyg 1998; 58:775-9.
7. Sher A, Hieny S, Joiner K. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate. J Immunol 1986; 137:2961-7.
8. Krettli AU, Pontes de Carvalho LC. Binding of C3 fragments to the T. cruzi surface in the absence of specific antibodies and without activation of the complement cascade. Clin Exp Immunol 1985; 62:270-7.
9. Krautz GM, Kissinger JC, Krettli AU. The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today 2000; 16:31-4.
10. Tambourgi DV. A partial cDNA clone of trypomastigote the decay accelerating factor (T-DAF), a developmentally regulated complement inhibitor of T. cruzi, has genetic and functional similarities to the human complement inhibitor DAF. Infect Immun 1993; 61:3656-63.
11. Norris KA. Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance. Infect Immun 1998; 66:2460-5.
12. Ferreira V, Valck C, Sanchez G, et al. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J Immunol 2004; 172:3042-50.
13. Fischer EM, Ouassi P, Velge J, Kazatchkine MC. gp58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from the human alternative complement pathway. Immunology 1988; 65:299-303.
14. Inal JM, Sim RB. A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Lett 2000; 470:131-4.
15. Inal JM, Hui KM, Miot S, et al. Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. J Immunol 2005; 174:356-66.
16. Inal JM, Schifferli JA. Complement C2 receptor inhibitor trispanning and the β-chain of C4 share a binding site for complement C2. J Immunol 2002; 168:5213-21.
17. Hui KM, Orriss GL, Schirmer T, Magnadottir B, Inal JM. Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT. Biochem J 2005; 389:863-8.
18. Buscaglia CA, Di Noia JM. The Trypanosoma cruzi clonal diversity and the epidemiology of Chagas' disease. Microbes Infect 2003; 5:419-27.
19. Briones MR, Souto RP, Stolf BS, Zingales B. The evolution of two Trypanosoma cruzi subgroups inferred from rRNA genes can be correlated with the interchange of American mammalian faunas in the Cenozoic and has implications to pathogenicity and host specificity. Mol Biochem Parasitol 1999; 104:219-32.
20. Fernandes O, Mangia RH, Lisboa CV, et al. The complexity of the sylvatic cycle of Trypanosoma cruzi in Rio de Janeiro state (Brazil) revealed by the non-transcribed spacer of the mini-exon gene. Parasitology 1999; 118:161-6.
21. Ramirez MI, Yamauchi LM, De Freitas Jr LH, Uemura H, Schenkman S. The use of the green fluorescent protein to monitor and improve transfection in Trypanosoma cruzi. Mol Biochem Parasitol 2000; 111:235-40.
22. Di Noia JM, Buscaglia CA, De Marchi CA, Almeida IC, Frasch AC. A Trypanosoma cruzi small surface molecule provides the first immunological evidence that Chagas' disease is due to a single parasite lineage. J Exp Med 2002; 195:401-13.
23. Ramirez MI, Ruiz RC, Araya JE, Da Silveira JF, Yoshida N. Involvement of the stage-specific 82-kilodalton adhesion molecule of Trypanosoma cruzi metacyclic trypomastigotes in host cell invasion. Infect Immun 1993; 61:3636-41.
24. Contreras VT, Salles JM, Thomas N, Morel CM, Goldenberg S. In vitro differentiation of Trypanosoma cruzi under chemically defined conditions. Mol Biochem Parasitol 1985; 16:315-27.
25. Inal JM. Complement C2 receptor inhibitor trispanning: from man to schistosome. Springer Semin Immunopathol 2005; 27:320-31.
26. Inal JM, Miot S, Schifferli JA. The complement inhibitor, CRIT, undergoes clathrin-dependent endocytosis. Exp Cell Res 2005; 310:54-65.
27. Dominguez M, Moreno I, Lopez-Trascasa M, Torano A. Complement interaction with trypanosomatid promastigotes in normal human serum. J Exp Med 2002; 195:451-9.
28. Nogueira N, Bianco C, Cohn Z. Studies on the selective lysis and purification of Trypanosoma cruzi. J Exp Med 1975; 142:224-9.
29. Ji YH, Fujita T, Hatsuse H, Takahashi A, Matsushita M, Kawakami M. Activation of the C4 and C2 components of complement by a proteinase in serum bactericidal factor, Ra reactive factor. J Immunol 1993; 150: 571-8.
30. Roos A, Bouwman LH, Munoz J, et al. Functional characterization of the lectin pathway of complement in human serum. Mol Immunol 2003; 39:655-68.
31. Khan S, Wleklinski M, Aruffo A, Farr A, Coder D, Khan M. Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor. J Exp Med 1995; 182:1243-58.
32. Peterslund NAC, Koch CC, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001; 358:637-8.
33. Dumestre-Perard C, Doerr E, Colomb MG, Loos M. Involvement of complement pathways in patients with bacterial septicemia. Mol Immunol 2007; 44:1631-8.
34. Tomlinson S, Raper J. The lysis of Trypanosoma brucei brucei by human serum. Nat Biotechnol 1996; 14:717-21.